How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Author:

Neumann Eva1,Schreeck Filippa1ORCID,Herberg Jethro2ORCID,Jacqz Aigrain Evelyne345ORCID,Maitland‐van der Zee Anke H.6,Pérez‐Martínez Antonio789,Hawcutt Daniel B.1011,Schaeffeler Elke1,Rane Anders12,de Wildt Saskia N.1314,Schwab Matthias115ORCID

Affiliation:

1. Dr Margarete Fischer‐Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen Tuebingen Germany

2. Department of Paediatric Infectious Disease, Faculty of Medicine Imperial College London London UK

3. Pediatric Pharmacology and Pharmacogenetics Hopital Universitaire Saint‐Louis Paris France

4. Clinical Investigation Center CIC1426 Hôpital Robert Debre Paris France

5. Pharmacology University of Paris Paris France

6. Department of Respiratory Medicine, Amsterdam UMC University of Amsterdam Amsterdam the Netherlands

7. Institute for Health Research La Paz University Hospital Madrid Spain

8. Pediatric Onco‐Hematology Department La Paz University Hospital Madrid Spain

9. Faculty of Medicine Autonomous University of Madrid Madrid Spain

10. Department of Women's and Children's Health University of Liverpool UK

11. NIHR Alder Hey Clinical Research Facility Alder Hey Children's Hospital Liverpool UK

12. Division of Clinical Pharmacology, Department of Laboratory Medicine Karolinska University Hospital, Karolinska Institutet Stockholm Sweden

13. Department of Pharmacology and Toxicology, Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen the Netherlands

14. Intensive Care and Department of Paediatric Surgery Erasmus MC‐Sophia Children's Hospital Rotterdam the Netherlands

15. Departments of Clinical Pharmacology, and Biochemistry and Pharmacy University of Tuebingen Tuebingen Germany

Funder

Horizon 2020 Framework Programme

Robert Bosch Stiftung

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference170 articles.

1. Defining drug response for stratified medicine

2. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

3. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines

4. Food and Drug Administration.Table of Pharmacogenomic Biomarkers in Drug Labeling.https://www.fda.gov/drugs/science‐and‐research‐drugs/table‐pharmacogenomic‐biomarkers‐drug‐labeling#:~:text=Table%20of%20Pharmacogenomic%20Biomarkers%20in%20Drug%20Labeling%20 and%20Admini%20… %20%2023%20more%20rows. Updated August 18 2020. Accessed December 31 2020.

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Artificial Intelligence in Pediatrics: Learning to Walk Together;Turkish Archives of Pediatrics;2024-03-01

2. Worldwide network initiatives in improving pediatric drug research;Essentials of Translational Pediatric Drug Development;2024

3. Principles of performing pediatric clinical drug trials;Essentials of Translational Pediatric Drug Development;2024

4. Pharmacogenomics in pediatric medicine and drug development;Pharmacogenomics;2022-08

5. Biomarker und Neuromonitoring zur Entwicklungsprognose nach perinataler Hirnschädigung;Monatsschrift Kinderheilkunde;2022-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3